125 related articles for article (PubMed ID: 36736154)
1. Discovery of novel and bioavailable histone deacetylases and cyclin-dependent kinases dual inhibitor to impair the stemness of leukemia cells.
Liu Y; Wei Y; Wang X; Ma L; Li X; Sun Y; Wu Y; Zhang L; Wang J; Li M; Zhang K; Wei M; Yang G; Yang C
Eur J Med Chem; 2023 Mar; 249():115140. PubMed ID: 36736154
[TBL] [Abstract][Full Text] [Related]
2. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia.
Fujita S; Honma D; Adachi N; Araki K; Takamatsu E; Katsumoto T; Yamagata K; Akashi K; Aoyama K; Iwama A; Kitabayashi I
Leukemia; 2018 Apr; 32(4):855-864. PubMed ID: 28951561
[TBL] [Abstract][Full Text] [Related]
4. HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.
Qi J; Singh S; Hua WK; Cai Q; Chao SW; Li L; Liu H; Ho Y; McDonald T; Lin A; Marcucci G; Bhatia R; Huang WJ; Chang CI; Kuo YH
Cell Stem Cell; 2015 Nov; 17(5):597-610. PubMed ID: 26387755
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3.
Wachholz V; Mustafa AM; Zeyn Y; Henninger SJ; Beyer M; Dzulko M; Piée-Staffa A; Brachetti C; Haehnel PS; Sellmer A; Mahboobi S; Kindler T; Brenner W; Nikolova T; Krämer OH
Arch Toxicol; 2022 Jan; 96(1):177-193. PubMed ID: 34665271
[TBL] [Abstract][Full Text] [Related]
6. A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor.
Li Y; Chen K; Zhou Y; Xiao Y; Deng M; Jiang Z; Ye W; Wang X; Wei X; Li J; Liang J; Zheng Z; Yao Y; Wang W; Li P; Xu B
Curr Cancer Drug Targets; 2015; 15(6):493-503. PubMed ID: 26282548
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.
Xu X; Xie C; Edwards H; Zhou H; Buck SA; Ge Y
PLoS One; 2011 Feb; 6(2):e17138. PubMed ID: 21359182
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.
Wiggers CRM; Govers AMAP; Lelieveld D; Egan DA; Zwaan CM; Sonneveld E; Coffer PJ; Bartels M
Pediatr Blood Cancer; 2019 Aug; 66(8):e27785. PubMed ID: 31044544
[TBL] [Abstract][Full Text] [Related]
9. Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?
Amin SA; Khatun S; Gayen S; Das S; Jha T
Eur J Med Chem; 2023 Oct; 258():115594. PubMed ID: 37429084
[TBL] [Abstract][Full Text] [Related]
10. Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells.
Romanski A; Schwarz K; Keller M; Wietbrauk S; Vogel A; Roos J; Oancea C; Brill B; Krämer OH; Serve H; Ruthardt M; Bug G
Cell Cycle; 2012 Sep; 11(17):3219-26. PubMed ID: 22895185
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.
Zhao J; Xie C; Edwards H; Wang G; Taub JW; Ge Y
Oncotarget; 2017 Jan; 8(4):6319-6329. PubMed ID: 28030834
[TBL] [Abstract][Full Text] [Related]
12. HDAC6 as a target for antileukemic drugs in acute myeloid leukemia.
Hackanson B; Rimmele L; Benkißer M; Abdelkarim M; Fliegauf M; Jung M; Lübbert M
Leuk Res; 2012 Aug; 36(8):1055-62. PubMed ID: 22464548
[TBL] [Abstract][Full Text] [Related]
13. T-17, a novel cyclin-dependent kinases/histone deacetylases dual inhibitor, induces cancer cells death through cell cycle arrest and apoptosis.
Zhang L; Long R; Li X; Jiang J; Chen H; Tian B; Long B; Yu Y; Gan Z
Drug Dev Res; 2022 Nov; 83(7):1578-1588. PubMed ID: 35844039
[TBL] [Abstract][Full Text] [Related]
14. HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.
Lai TH; Ewald B; Zecevic A; Liu C; Sulda M; Papaioannou D; Garzon R; Blachly JS; Plunkett W; Sampath D
Clin Cancer Res; 2016 Jul; 22(14):3537-49. PubMed ID: 26858310
[TBL] [Abstract][Full Text] [Related]
15. CaMKII exacerbates heart failure progression by activating class I HDACs.
Zhang M; Yang X; Zimmerman RJ; Wang Q; Ross MA; Granger JM; Luczak ED; Bedja D; Jiang H; Feng N
J Mol Cell Cardiol; 2020 Dec; 149():73-81. PubMed ID: 32971072
[TBL] [Abstract][Full Text] [Related]
16. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
[TBL] [Abstract][Full Text] [Related]
17. Lipids and the cancer stemness regulatory system in acute myeloid leukemia.
Lim INX; Nagree MS; Xie SZ
Essays Biochem; 2022 Sep; 66(4):333-344. PubMed ID: 35996953
[TBL] [Abstract][Full Text] [Related]
18. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
[TBL] [Abstract][Full Text] [Related]
19. CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia.
Liu Y; Wang G; Zhang J; Chen X; Xu H; Heng G; Chen J; Zhao Y; Li J; Ni Y; Zhang Y; Shan J; Qian C
Stem Cell Res Ther; 2021 Jan; 12(1):86. PubMed ID: 33494824
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach.
Lee DJ; Zeidner JF
Expert Opin Investig Drugs; 2019 Nov; 28(11):989-1001. PubMed ID: 31612739
[No Abstract] [Full Text] [Related]
[Next] [New Search]